Thyroid surgery for treatment of Graves’ disease complicated by ophthalmopathy: a comprehensive review

References

• Franklyn J, Boelaert K. Thyrotoxicosis. Lancet 2012;379(9821):1155-66
   PubMedGoogle Scholar
• Weetman A. Graves’ disease. N Engl J Med 2000;343(17):1236-48
   PubMed Web of Science ®Google Scholar
• Bahn R, Heufelder A. Pathogenesis of graves’ opthalmopathy. N Engl J Med 1993;329(20):1468-75
   PubMed Web of Science ®Google Scholar
• Muldoon BT, Mai VQ, Burch HB. Management of Graves’ disease: an overview and comparison of clinical practice guidelines with actual practice trends. Endocrinol Metab Clin North Am 2014;43(2):495-516
   PubMedGoogle Scholar
• Marcocci C, Bartalena L, Bogazzi F, et al. Studies on the occurrence of opthalmopathy in Graves’ disease. Acta Endocrinol 1989;120:473-8
   PubMedGoogle Scholar
• Bahn RS, Dutton CM, Natt N, et al. Thyrotropin receptor expression in Graves’ orbital adipose/connective tissues: potential autoantigen in Graves’ ophthalmopathy. J Clin Endocrinol Metab 1998;83(3):998-1002
   PubMed Web of Science ®Google Scholar
• Terwee C, Wakelkamp I, Tan S, et al. Long-term effects of Graves’ ophthalmopathy on health-related quality of life. Eur J Endocrinol 2002;146(6):751-7
   PubMed Web of Science ®Google Scholar
• Wiersinga W, Prummel M, Terwee C. Effects of Graves’ opthalmopathy on quality of life. J Endocrinol Invest 2004;27:259-64
   PubMed Web of Science ®Google Scholar
• Bunevicius R, Velickiene D, et al. Mood and anxiety disorders in women with treated hyperthyroidism and ophthalmopathy caused by Graves’ disease. Gen Hosp Psychitry 2005;27:133-9
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Petrak F, Hardt J, et al. Psychosocial morbidity of Graves’ orbitopathy. Clin Endocrinol (Oxf) 2005;63(4):395-402
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid 2008;18(3):333-46
   PubMed Web of Science ®Google Scholar
• Bahn R, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxcicosis: management guidelines of the american thyroid association and american association of clinical endocrinologists. Thyroid 2011;21(6):593-646
   PubMed Web of Science ®Google Scholar
• Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 2014;37(8):691-700
   PubMed Web of Science ®Google Scholar
• Mourits M, Koornneef L, Wiersinga W, et al. Clinical criteria for the assessment of disease activity in Graves’ opthalmopathy. Br J Opthalmol 1989;73:639-44
   PubMed Web of Science ®Google Scholar
• Mourits M, Prummel M, Wiersinga W, et al. Clinical activity score as a guide in the management of patients with Graves’ opthalmopathy. Clin Endocrinol 1997;47:9-14
   PubMed Web of Science ®Google Scholar
• Prummel MF, Wiersinga WM, Mourits MP, et al. Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med 1990;150(5):1098-101
   PubMedGoogle Scholar
• Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 2002;12(10):855-60
   PubMed Web of Science ®Google Scholar
• Kraimps JL, Bouin-Pineau MH, Mathonnet M, et al. Multicentre study of thyroid nodules in patients with Graves’ disease. Br J Surg 2000;87(8):1111-13
   PubMedGoogle Scholar
• Belfiore A, Russo D, Vigneri R, et al. Graves’ disease, thyroid nodules and thyroid cancer. Clin Endocrinol (Oxf) 2001;55(6):711-18
   PubMedGoogle Scholar
• Tamatea J, Tu’akoi K, Conaglen J, et al. Thyroid cancer in Graves’ disease: is surgery the best treatment for Graves’ disease? ANZ J Surg 2014;84(4):231-4
   PubMedGoogle Scholar
• Fugazzola L, Colombo C, Perrino M, et al. Papillary thyroid carcinoma and inflammation. Front Endocrinol 2011;2:88
   PubMedGoogle Scholar
• Pazaitou-Panayiotou K, Michalakis K, Paschke R. Thyroid cancer in patients with hyperthyroidism. Horm Metab Res 2012;44(4):255-62
   PubMed Web of Science ®Google Scholar
• Scerrino G, Morfino G, Paladino NC, et al. Does thyroid surgery for Graves’ disease improve health-related quality of life? Surg Today 2013;43(12):1398-405
   PubMedGoogle Scholar
• Grodski S, Stalberg P, Robinson BG, et al. Surgery versus radioiodine therapy as definitive management for graves’ disease: the role of patient preference. Thyroid 2007;17(2):157-60
   PubMedGoogle Scholar
• Palit TK, Miller CC, Miltenburg DM. The efficacy of thyroidectomy for Graves’ disease: a meta-analysis. J Surg Res 2000;90(2):161-5
   PubMedGoogle Scholar
• Guo Z, Yu P, Liu Z, et al. Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves’ diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol (Oxf) 2013;79(5):739-46
   PubMedGoogle Scholar
• Feroci F, Rettori M, Borrelli A, et al. A systematic review and meta-analysis of total thyroidectomy versus bilateral subtotal thyroidectomy for Graves’ disease. Surgery 2014;155(3):529-40
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, McHenry CR. Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves’ disease in the United States. World J Surg 2010;34(6):1261-4
   PubMed Web of Science ®Google Scholar
• Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab 2012;97(12):4549-58
   PubMed Web of Science ®Google Scholar
• Solomon B, Glinoer D, Lagasse R, et al. Current trends in the management of Graves’ disease. J Clin Endocrinol Metab 1990;70(6):1518-24
   PubMed Web of Science ®Google Scholar
• Yip J, Lang BHH, Lo CY. Changing trend in surgical indication and management for Graves’ disease. Am J Surg 2012;203(2):162-7
   PubMedGoogle Scholar
• Perros P, Baldeschi L, Boboridis K, et al. A questionnaire survey on the management of Graves’ orbitopathy in Europe. Eur J Endocrinol 2006;155(2):207-11
   PubMedGoogle Scholar
• Ramos HE, Diehl LA, Camacho CP, et al. Management of Graves’ orbitopathy in Latin America: an international questionnaire study compared with Europe. Clin Endocrinol (Oxf) 2008;69(6):951-6
   PubMedGoogle Scholar
• Snyder S, Govednik C, Lairmore T. Total Thyroidectomy as Primary Definitive Treatment for Graves’ Hyperthyroidism. American Surgeon 2013;79:1283-8
   PubMed Web of Science ®Google Scholar
• Weber KJ, Solorzano CC, Lee JK, et al. Thyroidectomy remains an effective treatment option for Graves’ disease. Am J Surg 2006;191(3):400-5
   PubMedGoogle Scholar
• Werga-Kjellman P, Zedenius J, Tallstedt L, et al. Surgical treatment of hyperthyroidism: a ten-year experience. Thyroid 2001;11(2):187-92
   PubMedGoogle Scholar
• Feliciano D V, Lyons JD. Thyroidectomy is optimal treatment for Graves’ disease. J Am Coll Surg 2011;212(4):714-21
   PubMedGoogle Scholar
• Genovese BM, Noureldine SI, Gleeson EM, et al. What is the best definitive treatment for Graves’ disease? A systematic review of the existing literature. Ann Surg Oncol 2013;20(2):660-7
   PubMedGoogle Scholar
• Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228(3):320-30
   PubMed Web of Science ®Google Scholar
• Liu J, Bargren A, Schaefer S, et al. Total thyroidectomy: a safe and effective treatment for Graves’ disease. J Surg Res 2011;168(1):1-4
   PubMedGoogle Scholar
• Alsanea O, Clark OH. Treatment of Graves’ disease: the advantages of surgery. Endocrinol Metab Clin North Am 2000;29(2):321-37
   PubMed Web of Science ®Google Scholar
• Carroll R, Matfin G. Endocrine and metabolic emergencies: thyroid storm. Ther Adv Endocrinol Metab 2010;1(3):139-45
   PubMedGoogle Scholar
• Zanocco K, Heller M, Elaraj D, et al. Is subtotal thyroidectomy a cost-effective treatment for Graves disease? A cost-effectiveness analysis of the medical and surgical treatment options. Surgery 2012;152(2):164-72
   PubMedGoogle Scholar
• In H, Pearce EN, Wong AK, et al. Treatment options for Graves disease: a cost-effectiveness analysis. J Am Coll Surg 2009;209(2):170-9
   PubMed Web of Science ®Google Scholar
• Moleti M, Mattina F, Salamone I, et al. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves’ opthalmopathy. Thyroid 2003;13(7):653-8
   PubMedGoogle Scholar
• Bartalena L. The dilemma of how to manage Graves’ hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 2011;96(3):592-9
   PubMedGoogle Scholar
• Bahn R. The EUGOGO consensus statement on the management of Graves’ orbitopathy: equally applicable to North American clinicians and patients. Thyroid 2008;18(3):281-2
   PubMedGoogle Scholar
• Witte J, Goretzki P, Dotzenrath C, et al. Surgery for Graves’ disease: total versus subtotal thyroidectomy - results of a prospective randomized trial. World J Surg 2000;24:1303-11
   PubMedGoogle Scholar
• Barczyński M, Konturek A, Hubalewska-Dydejczyk A, et al. Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves’ disease with a 5-year follow-up. Br J Surg 2012;99(4):515-22
   PubMedGoogle Scholar
• Bartalena L, Marcocci C, et al. Relation between therapy for hyperthyroidism and the course of Graves’ opthalmopathy. N Engl J Med 1998;338:73-8
   PubMed Web of Science ®Google Scholar
• Träisk F, Tallstedt L, Abraham-Nordling M, et al. Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009;94(10):3700-7
   PubMed Web of Science ®Google Scholar
• Acharya SH, Avenell A, Philip S, et al. Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf) 2008;69(6):943-50
   PubMedGoogle Scholar
• Tallstedt L, Lundell G, Torring O, et al. Occurrence of opthalmopathy after treatment for graves’ hypterthyroidism. N Engl J Med 1992;326(26):1733-8
   PubMed Web of Science ®Google Scholar
• Laurberg P, Krejbjerg A, Andersen SL. Relapse following antithyroid drug therapy for Graves’ hyperthyroidism. Curr Opin Endocrinol Diabetes Obes 2014;21(5):415-21
   PubMedGoogle Scholar
• Leo M, Marcocci C, Pinchera A, et al. Outcome of Graves’ orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab 2012;97(1):E44-8
   Google Scholar
• Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006;91(9):3464-70
   PubMed Web of Science ®Google Scholar
• Eckstein AK, Lax H, Lösch C, et al. Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol (Oxf) 2007;67(4):607-12
   PubMedGoogle Scholar
• Orgiazzi J, Madec A-M. Reduction of the risk of relapse after withdrawal of medical therapy for Graves’ disease. Thyroid 2002;12(10):849-53
   PubMedGoogle Scholar
• Lowery A, Kerin MJ. Grave’s Ophthalmopathy: the Case For Thyroid Surgery. R Coll Surg Edinburgh Irel 2009;7(5):290-6
   PubMedGoogle Scholar
• Bartalena L, Marcocci C, Lai A, et al. Graves hyperthyroidism of recent onset and Graves orbitopathy- to ablate or not to ablate the thyroid? J Endocrinol Invest 2008;31:578-81
   PubMedGoogle Scholar
• De Groot L, Benjasuratwong Y. Evaluation of thyroid ablative therapy for opthalmopathy of Graves’ disease. Orbit 1996;15:187-96
   Google Scholar
• Menconi F, Marinò M, Pinchera A, et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 2007;92(5):1653-8
   PubMed Web of Science ®Google Scholar
• Chiovato L, Latrofa F, Braverman LE, et al. Brief communication disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003;139:346-51
   PubMed Web of Science ®Google Scholar
• De Bellis A, Conzo G, Cennamo G, et al. Time course of Graves’ ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine 2012;41(2):320-6
   PubMedGoogle Scholar
• Tanda ML, Piantanida E, Bartalena L. Treating Graves’ orbitopathy: where are we? Endocrine 2012;41(2):167-8
   PubMedGoogle Scholar
• Yang Z, Shi W, Zhu B, et al. Prevalence and risk of cancer of thyroid incidentaloma identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography. J Otolaryngol Head Neck Surg 2012;41(5):327-33
   PubMedGoogle Scholar
• Du P, Ma X, Wang C. Associations of CTLA4 Gene Polymorphisms with Graves’ Ophthalmopathy: a Meta-Analysis. Int J Genomics 2014;2014(1):537969
   PubMedGoogle Scholar
• Iyer NG, Shaha AR, Silver CE, et al. Thyroid incidentalomas: to treat or not to treat. Eur Arch Otorhinolaryngol 2010;267(7):1019-26
   PubMedGoogle Scholar
• Yin X, Sachidanandam R, Morshed S, et al. mRNA-Seq reveals novel molecular mechanisms and a robust fingerprint in graves’ disease. J Clin Endocrinol Metab 2014;99(10):E2076-83
   Google Scholar
• Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2014;13(3):272-80
   PubMed Web of Science ®Google Scholar
• De Juan EJ, Hurley D, Sapira J. Racial differences in normal values of proptosis. Arch Intern Med 1980;140:1230-1
   PubMedGoogle Scholar
• Sarinnapakorn V, Sridama V, Sunthornthepvarakul T. Proptosis in normal Thai samples and thyroid patients. J Med Assoc Thai 2007;90:679-83
   PubMedGoogle Scholar
• Tsai C, Kau H, Kau S, Hsu W. Exophthalmos of patients with GD in Chinese of Taiwan. Eye 2006;20:569-73
   PubMed Web of Science ®Google Scholar
• Winsa B, Rastad J, Akerström G, et al. Retrospective evaluation of subtotal and total thyroidectomy in Graves’ disease with and without endocrine ophthalmopathy. Eur J Endocrinol 1995;132(4):406-12
   PubMedGoogle Scholar
• Miccoli P, Vitti P, Rago T, et al. Surgical treatment of Graves’ disease: subtotal or total thyroidectomy? Surgery 1996;120(6):1020-5
   PubMedGoogle Scholar
• Agarwal A, Mishra SK. Role of surgery in the management of Graves’ disease. J Indian Med Assoc 2001;99(5):252; 254-6
   PubMedGoogle Scholar
• Kurihara H. Total thyroidectomy for the treatment of hyperthyroidism in patients with ophthalmopathy. Thyroid 2002;12(3):265-7
   PubMed Web of Science ®Google Scholar
• Järhult J, Rudberg C, Larsson E, et al. Graves’ disease with moderate-severe endocrine ophthalmopathy-long term results of a prospective, randomized study of total or subtotal thyroid resection. Thyroid 2005;15(10):1157-64
   PubMedGoogle Scholar
• Konturek A, Barczyński M, Chichon S, et al. Total Thyroidectomy in Treatment of Graves’ Ophthalmopathy. Polish J Surg 2008;80(9):455-64
   Google Scholar
• Nart A, Uslu A, Aykas A, et al. Total thyroidectomy for the treatment of recurrent graves’ disease with ophthalmopathy. Asian J Surg 2008;31(3):115-18
   PubMedGoogle Scholar
• Maurer E, Dănilă R, Dominguez E, et al. Long-term results of surgical treatment in Graves’ disease orbitopathy. Is there a correlation between the extent of thyroidectomy and the course of orbithopathy? Chirurgia (Bucur) 2008;103(3):291-5
   PubMedGoogle Scholar
• Elsayed YA, Abdul-Latif AM, Abu-Alhuda MF, et al. Effect of near-total thyroidectomy on thyroid orbitopathy due to toxic goiter. World J Surg 2009;33(4):758-66
   PubMedGoogle Scholar